Marie Dreyer

ORCID: 0009-0001-0827-057X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Gastric Cancer Management and Outcomes
  • Immunotherapy and Immune Responses
  • Economic and Financial Impacts of Cancer
  • Health Policy Implementation Science
  • Complement system in diseases
  • Estrogen and related hormone effects
  • Biomedical and Engineering Education
  • Renal Diseases and Glomerulopathies
  • Interprofessional Education and Collaboration
  • Neutropenia and Cancer Infections
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Pharmaceutical Economics and Policy
  • Global Cancer Incidence and Screening
  • Pancreatic and Hepatic Oncology Research
  • Inflammatory mediators and NSAID effects
  • Cancer survivorship and care
  • Esophageal Cancer Research and Treatment
  • HER2/EGFR in Cancer Research
  • Radiomics and Machine Learning in Medical Imaging
  • Biosimilars and Bioanalytical Methods
  • Primary Care and Health Outcomes

Northwestern University
2023-2024

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2023-2024

University of Chicago
2021-2024

Thrombotic thrombocytopenic purpura (TTP) is not uncommonly seen in pregnancy, either with the first episode or exacerbation of known disease. The management TTP pregnancy can be challenging if there refractoriness to use therapeutic plasma exchange (TPE) and high-dose corticosteroids. Caplacizumab, a vWF-directed humanized antibody fragment, approved for treatment acquired but sparse data on its pregnant patients. Antenatal peripartum haemorrhage theoretical concern medication obstetric...

10.1111/bjh.18888 article EN cc-by-nc-nd British Journal of Haematology 2023-05-24

Abstract Patients with breast cancer frequently experience financial hardship, often due to the high costs of anti-cancer drugs. We sought develop alternative trastuzumab dosing strategies, compare their pharmacokinetic effectiveness standard dosing, and assess expected implications transitioning them. extracted clinical data from records 135 retrospectively identified patients HER2-positive early at a single, urban comprehensive center who were treated between 2017 2019. performed...

10.1038/s41523-022-00393-2 article EN cc-by npj Breast Cancer 2022-03-14

In a large academic medical center, processes for ordering and receiving biomarker testing to inform cancer treatment in non–small cell lung varied by whether tests were conducted internally or externally. Lack of standardization processes, despite the availability electronic health record solutions, contributes clinician burden may increase risk delays receipt results; therefore, efforts streamline benefit systems.

10.1002/cncr.35240 article EN cc-by-nc-nd Cancer 2024-02-14

Doublet platinum or taxane-based therapies are the current standard backbone of treatment for advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. Previously used anthracycline-based triplet regimens no longer routinely due to toxicity and lack superior efficacy. We hypothesized that addition nab-paclitaxel FOLFOX (FOLFOX-A) would induce higher efficacy better tolerability.

10.1093/oncolo/oyae236 article EN cc-by The Oncologist 2024-09-18

In early-stage, triple-negative breast cancer (TNBC), immune cell infiltration contributes to survival, tumor invasion, and metastasis. High TNBC glucocorticoid receptor (GR) expression in early-stage is associated with poor long-term outcomes; it unknown if high GR an immunosuppressed microenvironment. We hypothesized that would be immune-suppressed microenvironment, which could thus account for the prognosis observed GR-positive TNBC. Formalin fixed-paraffin embedded tissue (n = 47) from...

10.1007/s10549-024-07515-3 article EN cc-by-nc-nd Breast Cancer Research and Treatment 2024-11-23

e18828 Background: Trastuzumab-related costs of human epidermal growth factor receptor 2 (HER2) positive breast cancer treatment are significant, approaching $70,000 per patient in the adjuvant setting alone. Recently developed population pharmacokinetic models demonstrate that therapeutic levels trastuzumab maintained despite decreased maintenance dose or frequency, potentially improving trastuzumab’s value proposition. In this observational study, we evaluate potential patient- and health...

10.1200/jco.2021.39.15_suppl.e18828 article EN Journal of Clinical Oncology 2021-05-20

Abstract Background: Triple-negative breast cancer (TNBC) with high glucocorticoid receptor activity (GR-high) is associated a risk of relapse and chemotherapy resistance. Glucocorticoids (GC) are essential for the regulation immune inflammatory responses. Multiple mechanisms GC-induced immunosuppression have been proposed, including suppression T cell proliferation dendritic antigen presentation function. The importance intact surveillance in controlling neoplastic transformation...

10.1158/1538-7445.sabcs20-ps18-01 article EN Cancer Research 2021-02-15

258 Background: The use of the Emergency Department (ED) by oncology patients for lower acuity issues is common. Oncology Rapid Assessment Clinics (ORAC) may play a key role in reducing ED visits among patients. We analyzed whether advent ORAC was associated with utilization receiving cancer care at University Chicago Medical Center (UCMC). Methods: UCMC opened its March 2019 to provide supportive and symptom management who needed acute medical addressed. To identify active patients, we...

10.1200/jco.2020.39.28_suppl.258 article EN Journal of Clinical Oncology 2021-09-21
Coming Soon ...